Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Other Non-Current Liabilities (2021 - 2025)

Historic Other Non-Current Liabilities for Neuphoria Therapeutics (NEUP) over the last 5 years, with Q4 2025 value amounting to $2.7 million.

  • Neuphoria Therapeutics' Other Non-Current Liabilities rose 23485.99% to $2.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.7 million, marking a year-over-year increase of 23485.99%. This contributed to the annual value of $3.7 million for FY2025, which is N/A changed from last year.
  • According to the latest figures from Q4 2025, Neuphoria Therapeutics' Other Non-Current Liabilities is $2.7 million, which was up 23485.99% from $8.1 million recorded in Q3 2025.
  • Neuphoria Therapeutics' 5-year Other Non-Current Liabilities high stood at $8.1 million for Q3 2025, and its period low was $7492.2 during Q2 2022.
  • Over the past 5 years, Neuphoria Therapeutics' median Other Non-Current Liabilities value was $1.7 million (recorded in 2024), while the average stood at $2.2 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 9980.79% in 2023, then soared by 37838.02% in 2025.
  • Neuphoria Therapeutics' Other Non-Current Liabilities (Quarter) stood at $1.3 million in 2021, then tumbled by 99.43% to $7492.2 in 2022, then soared by 99.81% to $14969.9 in 2023, then skyrocketed by 5311.68% to $810125.0 in 2024, then skyrocketed by 234.86% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q4 2025, $8.1 million for Q3 2025, and $3.7 million during Q2 2025.